Safety Evaluation of Vyosadi Guggulu, an Ayurvedic Formulation through Acute and Subchronic Toxicity Studies in Wistar Rats
The objective of this study is to assess the safety profiles of Ayurvedic formulation Vyosadi guggulu (VG) in Wistar rats. Acute, subacute and subchronic toxicity studies were conducted in accordance with the guidelines of Organization for Economic Cooperation and Development (OECD) and the Committee for Control and Supervision of Experiments on Animals (CCSEA). Approvals from the Institutional Animal Ethics Committee (IAEC), Central Ayurveda Research Institute, Kolkata were obtained prior to carry out the animal experimental studies. Standardized trial drug VG supplied by Indian Medicine Pharmaceutical Corporation Limited (IMPCL), Uttarakhand. A single dose of VG at 2000mg/kg body weight was given to Wistar rats through oral gavage in acute toxicity study. Subchronic oral toxicity study was conducted out at three doses 250, 500 and 1000 mg/kg body weight and administered orally daily for 90 successive days. The doses were derived from a 28 days repeated dose oral toxicity study. Animals in the acute toxicity study were monitored for gross pathological examination, weekly feed and intake, mortality, weekly body weight changes, and general clinical symptoms. Animals were examined for mortality, weekly changes in body weight, general clinical signs, weekly feed and water intake, clinical biochemical investigations, hematological parameter analysis, examination for gross pathological changes, organ weight measurement, and histopathological investigations in the 90-day toxicity study. In acute toxicity study, the single dose of 2000mg/kg of VG was found to be safe. In 28 days and 90 days repeated dose oral toxicity studies all tested doses of VG were proven to be safe. In both studies, there was no significant adverse effect in food and water consumptions, hematological and clinical biochemistry parameters at any dose. No treatment related abnormal features were noticed during histopathological evaluation in 90 days oral toxicity study. The no observed adverse effect le